Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 3;6(5). pii: e590. doi: 10.1212/NXI.0000000000000590. Print 2019 Sep.

2.

Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH Study.

Hartung HP, Mallick R, Bril V, Lewis RA, Sobue G, Lawo JP, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, van Schaik IN; PATH study group.

Eur J Neurol. 2019 Aug 10. doi: 10.1111/ene.14056. [Epub ahead of print]

PMID:
31400231
3.

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 3;6(5):e590. doi: 10.1212/NXI.0000000000000590. eCollection 2019 Sep.

4.

Toxic neuropathies: Chemotherapy Induced Peripheral Neurotoxicity.

Alberti P, Cavaletti G, Cornblath DR.

Curr Opin Neurol. 2019 Oct;32(5):676-683. doi: 10.1097/WCO.0000000000000724.

PMID:
31306214
5.

Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings.

Argyriou AA, Park SB, Islam B, Tamburin S, Velasco R, Alberti P, Bruna J, Psimaras D, Cavaletti G, Cornblath DR; Toxic Neuropathy Consortium (TNC).

J Neurol Neurosurg Psychiatry. 2019 Jun 29. pii: jnnp-2019-320969. doi: 10.1136/jnnp-2019-320969. [Epub ahead of print] Review.

PMID:
31256000
6.

Current treatment practice of Guillain-Barré syndrome.

Verboon C, Doets AY, Galassi G, Davidson A, Waheed W, Péréon Y, Shahrizaila N, Kusunoki S, Lehmann HC, Harbo T, Monges S, Van den Bergh P, Willison HJ, Cornblath DR, Jacobs BC; IGOS Consortium.

Neurology. 2019 Jul 2;93(1):e59-e76. doi: 10.1212/WNL.0000000000007719. Epub 2019 Jun 7.

PMID:
31175208
7.

Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA.

Lancet Neurol. 2019 Aug;18(8):784-794. doi: 10.1016/S1474-4422(19)30144-9. Epub 2019 May 7. Review.

PMID:
31076244
8.

Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity.

Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Alberti P, Bruna J, Argyriou AA, Briani C, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Faber CG, Lalisang RI, Brandsma D, Koeppen S, Kerrigan S, Schenone A, Grisold W, Mazzeo A, Padua L, Dorsey SG, Penas-Prado M, Valsecchi MG; CI-PeriNomS Group.

J Peripher Nerv Syst. 2019 Mar;24(1):111-119. doi: 10.1111/jns.12306. Epub 2019 Feb 8.

PMID:
30672664
9.

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.

Merkies ISJ, van Schaik IN, Léger JM, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Durn BL, Cornblath DR, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Tackenberg B, Mielke O; PRIMA Trial Investigators and the PATH Study Group.

J Peripher Nerv Syst. 2019 Mar;24(1):48-55. doi: 10.1111/jns.12302. Epub 2019 Feb 15.

10.

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.

Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, Hartung HP, Lewis RA, Merkies ISJ, Sobue G, Durn B, Shebl A, van Schaik IN; PATH study group.

J Peripher Nerv Syst. 2019 Mar;24(1):72-79. doi: 10.1111/jns.12303. Epub 2019 Mar 1.

11.

Regional variation of Guillain-Barré syndrome.

Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, Claeys KG, Dardiotis E, Davidson A, van Doorn PA, Feasby TE, Galassi G, Gorson KC, Hartung HP, Hsieh ST, Hughes RAC, Illa I, Islam B, Kusunoki S, Kuwabara S, Lehmann HC, Miller JAL, Mohammad QD, Monges S, Nobile Orazio E, Pardo J, Pereon Y, Rinaldi S, Querol L, Reddel SW, Reisin RC, Shahrizaila N, Sindrup SH, Waqar W, Jacobs BC; IGOS Consortium.

Brain. 2018 Oct 1;141(10):2866-2877. doi: 10.1093/brain/awy232.

12.

Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.

Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, Cornblath DR, van Doorn PA; Dutch GBS Study Group.

J Peripher Nerv Syst. 2018 Dec;23(4):210-215. doi: 10.1111/jns.12286. Epub 2018 Sep 24.

PMID:
30151941
13.

IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG.

Berger M, Harbo T, Cornblath DR, Mielke O.

Immunotherapy. 2018 Aug;10(11):919-933. doi: 10.2217/imt-2018-0036. Epub 2018 May 16. Review.

PMID:
29764262
14.

A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.

Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA.

J Peripher Nerv Syst. 2018 Jun;23(2):108-114. doi: 10.1111/jns.12267. Epub 2018 Apr 26.

15.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.

van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group.

Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Erratum in: Lancet Neurol. 2018 Jan;17 (1):26. Erratum in: Lancet Neurol. 2018 Aug;17(8):661.

PMID:
29122523
16.

Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl.

Hughes RAC, Cornblath DR, Willison HJ.

Brain. 2016 Nov 1;139(11):3041-3047. doi: 10.1093/brain/aww247. No abstract available.

PMID:
29106487
17.

Pain in chemotherapy-induced peripheral neurotoxicity.

Marmiroli P, Scuteri A, Cornblath DR, Cavaletti G.

J Peripher Nerv Syst. 2017 Sep;22(3):156-161. doi: 10.1111/jns.12226. Epub 2017 Jul 2. Review.

PMID:
28600844
18.

International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome.

Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, Harbo T, Hartung HP, Hughes RAC, Kusunoki S, van Doorn PA, Willison HJ; IGOS Consortium.

J Peripher Nerv Syst. 2017 Jun;22(2):68-76. doi: 10.1111/jns.12209.

PMID:
28406555
19.

Differentiating lower motor neuron syndromes.

Garg N, Park SB, Vucic S, Yiannikas C, Spies J, Howells J, Huynh W, Matamala JM, Krishnan AV, Pollard JD, Cornblath DR, Reilly MM, Kiernan MC.

J Neurol Neurosurg Psychiatry. 2017 Jun;88(6):474-483. doi: 10.1136/jnnp-2016-313526. Epub 2016 Dec 21. Review.

20.

Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia.

Parra B, Lizarazo J, Jiménez-Arango JA, Zea-Vera AF, González-Manrique G, Vargas J, Angarita JA, Zuñiga G, Lopez-Gonzalez R, Beltran CL, Rizcala KH, Morales MT, Pacheco O, Ospina ML, Kumar A, Cornblath DR, Muñoz LS, Osorio L, Barreras P, Pardo CA.

N Engl J Med. 2016 Oct 20;375(16):1513-1523. Epub 2016 Oct 5.

21.

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.

van Schaik IN, van Geloven N, Bril V, Hartung HP, Lewis RA, Sobue G, Lawo JP, Mielke O, Cornblath DR, Merkies IS; PATH study group.

Trials. 2016 Jul 25;17(1):345. doi: 10.1186/s13063-016-1466-2.

22.

Correlation of the patient's reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies.

Draak TH, Gorson KC, Vanhoutte EK, van Nes SI, van Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS; PeriNomS Study Group.

Eur J Neurol. 2016 Jul;23(7):1248-53. doi: 10.1111/ene.13025. Epub 2016 Apr 29.

PMID:
27129110
23.

Does ability to walk reflect general functionality in inflammatory neuropathies?

Draak TH, Gorson KC, Vanhoutte EK, van Nes SI, van Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS; PeriNomS Study Group.

J Peripher Nerv Syst. 2016 Jun;21(2):74-81. doi: 10.1111/jns.12167.

PMID:
26968437
24.

Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS(©) ).

Vanhoutte EK, Faber CG, van Nes SI, Cats EA, Van der Pol WL, Gorson KC, van Doorn PA, Cornblath DR, van den Berg LH, Merkies IS; PeriNomS Study Group.

J Peripher Nerv Syst. 2015 Sep;20(3):296-305. doi: 10.1111/jns.12141. Erratum in: J Peripher Nerv Syst. 2016 Mar;21(1):55.

PMID:
26329270
25.

Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc(©) ) in patients with chemotherapy-induced peripheral neuropathy.

Binda D, Cavaletti G, Cornblath DR, Merkies IS; CI-PeriNomS study group.

J Peripher Nerv Syst. 2015 Sep;20(3):328-32. doi: 10.1111/jns.12140.

PMID:
26306547
26.

Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar.

Draak TH, Pruppers MH, van Nes SI, Vanhoutte EK, Bakkers M, Gorson KC, Van der Pol WL, Lewis RA, Notermans NC, Nobile-Orazio E, Léger JM, Van den Bergh PY, Lauria G, Bril V, Katzberg H, Lunn MP, Pouget J, van der Kooi AJ, van den Berg LH, van Doorn PA, Cornblath DR, Hahn AF, Faber CG, Merkies IS; PeriNomS study group.

J Peripher Nerv Syst. 2015 Sep;20(3):269-76. doi: 10.1111/jns.12126.

PMID:
26115516
27.

Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison.

Vanhoutte EK, Draak TH, Gorson KC, van Nes SI, Hoeijmakers JG, Van der Pol WL, Notermans NC, Lewis RA, Nobile-Orazio E, Léger JM, Van den Bergh PY, Lauria G, Bril V, Katzberg H, Lunn MP, Pouget J, van der Kooi AJ, Hahn AF, van Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS; PeriNomS Study Group.

J Peripher Nerv Syst. 2015 Sep;20(3):289-95. doi: 10.1111/jns.12118.

PMID:
26114893
28.

Comparing the NIS vs. MRC and INCAT sensory scale through Rasch analyses.

Draak TH, Vanhoutte EK, van Nes SI, Gorson KC, Van der Pol WL, Notermans NC, Nobile-Orazio E, Lewis RA, Léger JM, Van den Bergh PY, Lauria G, Bril V, Katzberg H, Lunn MP, Pouget J, van der Kooi AJ, Hahn AF, van den Berg LH, van Doorn PA, Cornblath DR, Faber CG, Merkies IS; PeriNomS Study Group.

J Peripher Nerv Syst. 2015 Sep;20(3):277-88. doi: 10.1111/jns.12127.

PMID:
26110493
29.

Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness.

Draak TH, Vanhoutte EK, van Nes SI, Gorson KC, Van der Pol WL, Notermans NC, Nobile-Orazio E, Léger JM, Van den Bergh PY, Lauria G, Bril V, Katzberg H, Lunn MP, Pouget J, van der Kooi AJ, Hahn AF, Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies IS; PeriNomS Study Group.

Neurology. 2014 Dec 2;83(23):2124-32. doi: 10.1212/WNL.0000000000001044. Epub 2014 Nov 5.

PMID:
25378677
30.

Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study.

Griffith KA, Dorsey SG, Renn CL, Zhu S, Johantgen ME, Cornblath DR, Argyriou AA, Cavaletti G, Merkies IS, Alberti P, Postma TJ, Rossi E, Frigeni B, Bruna J, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey DJ, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG; CI-PeriNomS Group.

J Peripher Nerv Syst. 2014 Jun;19(2):127-35. doi: 10.1111/jns5.12064.

31.

Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.

Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G; CI-PeriNomS Group.

Ann Oncol. 2014 Jan;25(1):257-64. doi: 10.1093/annonc/mdt409. Epub 2013 Nov 19.

32.

A dominant mutation in FBXO38 causes distal spinal muscular atrophy with calf predominance.

Sumner CJ, d'Ydewalle C, Wooley J, Fawcett KA, Hernandez D, Gardiner AR, Kalmar B, Baloh RH, Gonzalez M, Züchner S, Stanescu HC, Kleta R, Mankodi A, Cornblath DR, Boylan KB, Reilly MM, Greensmith L, Singleton AB, Harms MB, Rossor AM, Houlden H.

Am J Hum Genet. 2013 Nov 7;93(5):976-83. doi: 10.1016/j.ajhg.2013.10.006. Epub 2013 Oct 24.

33.

Meeting report: 2013 Peripheral Nerve Society Biennial Meeting, Saint-Malo, France, June 29-July 3, 2013.

Nobile-Orazio E, Léger JM, Lewis RA, Bolino A, Shy ME, Cornblath DR.

J Peripher Nerv Syst. 2013 Sep;18(3):197-8. doi: 10.1111/jns5.12041. No abstract available.

PMID:
24028187
34.

Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment.

Stork AC, Notermans NC, Vrancken AF, Cornblath DR, van der Pol WL.

J Peripher Nerv Syst. 2013 Jun;18(2):189-91. doi: 10.1111/jns5.12018. No abstract available.

PMID:
23781968
35.

Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).

Binda D, Vanhoutte EK, Cavaletti G, Cornblath DR, Postma TJ, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Rossi E, Valsecchi MG, Faber CG, Merkies IS; CI-PeriNomS study group, Galimberti S, Lanzani F, Mattavelli L, Piatti ML, Bidoli P, Cazzaniga M, Cortinovis D, Lucchetta M, Campagnolo M, Bakkers M, Brouwer B, Boogerd W, Grant R, Reni L, Piras B, Pessino A, Padua L, Granata G, Leandri M, Ghignotti I, Plasmati R, Pastorelli F, Heimans JJ, Eurelings M, Meijer RJ, Grisold W, Lindeck Pozza E, Mazzeo A, Toscano A, Russo M, Tomasello C, Altavilla G, Penas Prado M, Dominguez Gonzalez C, Dorsey SG.

Eur J Cancer. 2013 Sep;49(13):2910-8. doi: 10.1016/j.ejca.2013.04.004. Epub 2013 May 10.

PMID:
23668917
36.

Observations on chronic inflammatory demyelinating polyneuropathy: A plea for a rigorous approach to diagnosis and treatment.

Cornblath DR, Gorson KC, Hughes RA, Merkies IS.

J Neurol Sci. 2013 Jul 15;330(1-2):2-3. doi: 10.1016/j.jns.2013.04.015. Epub 2013 May 8. No abstract available.

PMID:
23663896
37.

Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery.

Müller T, van Laar T, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, Antonini A.

Parkinsonism Relat Disord. 2013 May;19(5):501-7 ; discussion 501. doi: 10.1016/j.parkreldis.2013.02.006. Epub 2013 Feb 27. Review.

38.

Therapeutic plasma exchange in neurology: 2012.

Cortese I, Cornblath DR.

J Clin Apher. 2013 Feb;28(1):16-9. doi: 10.1002/jca.21266. Review.

39.

The Jack Griffin Memorial Symposium.

Cornblath DR.

J Peripher Nerv Syst. 2012 Dec;17 Suppl 3:1. doi: 10.1111/j.1529-8027.2012.00421.x. No abstract available.

PMID:
23279422
40.

The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.

Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG; CI-PeriNomS Group.

Ann Oncol. 2013 Feb;24(2):454-62. doi: 10.1093/annonc/mds329. Epub 2012 Aug 21.

41.

The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.

Cornblath DR, Bienen EJ, Blight AR.

Clin Ther. 2012 May;34(5):1056-69. doi: 10.1016/j.clinthera.2012.03.007. Epub 2012 Apr 11. Review.

PMID:
22497693
42.

Modifying the Medical Research Council grading system through Rasch analyses.

Vanhoutte EK, Faber CG, van Nes SI, Jacobs BC, van Doorn PA, van Koningsveld R, Cornblath DR, van der Kooi AJ, Cats EA, van den Berg LH, Notermans NC, van der Pol WL, Hermans MC, van der Beek NA, Gorson KC, Eurelings M, Engelsman J, Boot H, Meijer RJ, Lauria G, Tennant A, Merkies IS; PeriNomS Study Group.

Brain. 2012 May;135(Pt 5):1639-49. doi: 10.1093/brain/awr318. Epub 2011 Dec 20.

43.

Comment on research report by Gruson and colleagues, this issue.

Huff CA, Merkies IS, Hughes RA, Cornblath DR.

J Peripher Nerv Syst. 2011 Sep;16(3):157-8. doi: 10.1111/j.1529-8027.2011.00349.x. No abstract available.

PMID:
22003928
44.

Guillain-Barré Syndrome in India: population-based validation of the Brighton criteria.

Mateen FJ, Cornblath DR, Jafari H, Shinohara RT, Khandit D, Ahuja B, Bahl S, Sutter RW.

Vaccine. 2011 Dec 6;29(52):9697-701. doi: 10.1016/j.vaccine.2011.09.123. Epub 2011 Oct 11.

45.

Dominant GDAP1 mutations cause predominantly mild CMT phenotypes.

Zimoń M, Baets J, Fabrizi GM, Jaakkola E, Kabzińska D, Pilch J, Schindler AB, Cornblath DR, Fischbeck KH, Auer-Grumbach M, Guelly C, Huber N, De Vriendt E, Timmerman V, Suter U, Hausmanowa-Petrusewicz I, Niemann A, Kochański A, De Jonghe P, Jordanova A.

Neurology. 2011 Aug 9;77(6):540-8. doi: 10.1212/WNL.0b013e318228fc70. Epub 2011 Jul 13.

46.

Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A.

Neurology. 2011 Jan 18;76(3):294-300. doi: 10.1212/WNL.0b013e318207b1f6. Review.

47.

Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice.

Gorson KC, van Schaik IN, Merkies IS, Lewis RA, Barohn RJ, Koski CL, Cornblath DR, Hughes RA, Hahn AF, Baumgarten M, Goldstein J, Katz J, Graves M, Parry G, van Doorn PA.

J Peripher Nerv Syst. 2010 Dec;15(4):326-33. doi: 10.1111/j.1529-8027.2010.00284.x.

PMID:
21199104
48.

Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties.

Griffith KA, Merkies IS, Hill EE, Cornblath DR.

J Peripher Nerv Syst. 2010 Dec;15(4):314-25. doi: 10.1111/j.1529-8027.2010.00292.x. Review.

PMID:
21199103
49.

An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy.

Chaudhry V, Cornblath DR.

J Peripher Nerv Syst. 2010 Sep;15(3):196-201. doi: 10.1111/j.1529-8027.2010.00270.x.

PMID:
21040141
50.

Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.

Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, Burwen DR, Cornblath DR, Cleerbout J, Edwards KM, Heininger U, Hughes R, Khuri-Bulos N, Korinthenberg R, Law BJ, Munro U, Maltezou HC, Nell P, Oleske J, Sparks R, Velentgas P, Vermeer P, Wiznitzer M; Brighton Collaboration GBS Working Group.

Vaccine. 2011 Jan 10;29(3):599-612. doi: 10.1016/j.vaccine.2010.06.003. Epub 2010 Jun 18. Review. No abstract available.

PMID:
20600491

Supplemental Content

Loading ...
Support Center